- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06328530
Itch Sensation Induced by Simultaneous Application of Pruritogens (Spatial Summation)
Repetitive Applications of Pruritogens and Effects of a Cutaneous-induced Pain Stimulation on Nonhistaminergic Itch Perception
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Silvia Lo Vecchio, PhD
- Phone Number: +4521397785
- Email: slv@hst.aau.dk
Study Contact Backup
- Name: Giulia Erica Aliotta, PhD
- Phone Number: 50290580
- Email: gea@hst.aau.dk
Study Locations
-
-
-
Aalborg, Denmark, 9620
- Recruiting
- Aalborg University
-
Contact:
- Silvia Lo Vecchio
- Phone Number: +4521397785
- Email: slv@hst.aau.dk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy men and women
- 18-60 years
- Speak and understand English
Exclusion Criteria:
- Pregnancy or lactation
- Drug addiction defined as any use of cannabis, opioids, or other addictive drugs
- Previous or current history of neurological (e.g. neuropathy), immunological (e.g. asthma, immune deficiencies, arthritis) musculoskeletal (e.g. muscular pain in the upper extremities,), cardiac disorder, or mental illnesses that may affect the results
- Lack of ability to cooperate
- Current use of medications that may affect the trial such as antihistamines, antipsychotics, and pain killers, as well as systemic or topical steroids
- Skin diseases (e.g. atopic dermatitis, pruritus nodularis, eczema, psoriasis)
- Moles, scars, or tattoos in the area to be treated or tested.
- Consumption of alcohol or painkillers 24 hours before the study days and between these
- Acute or chronic pain
- Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 1st pruritogen
The subproject consists of 2 sessions 3 days apart. Each session consists of 3 parts. In the first session, 3 test areas (4x4 cm) will be selected on the subject's forearms. In part 1, we will apply cowhage in one area. In part 2, we will apply cowhage in two areas on the same arm. In part 3, we will again apply cowhage in 2 areas, one on each arm. In each part, the itch intensity will be measured using a VAS (visual analog scale) for 10 min from the cowhage application. After removal of the cowhage, alloknesis and mechanically evoked itch will be measured in the area selected in part 1. |
25 spicules will be inserted in the center of the predefined skin area on the mandibular area.
The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
|
|
Other: 2nd pruritogen
The second session will take place 3 days after the first one and will follow the same procedure as session 1.
However, histamine will be applied instead of cowhage.
The order of the two sessions will be randomized.
|
Histaminergic itch will be evoked by a 1% histamine solution.
A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assessment of itch
Time Frame: 1 minute after every itch inductions
|
Immediately following the itch provocations, participants will be instructed to rate the itch intensity for 10 minutes using a digital visual analogue scale (VAS; eVAS Software: Aalborg, University, Denmark), on a tablet.
The scale will be measured from 0 to 100, where 0 represents 'no itch' and 100 'worst itch imaginable'.
|
1 minute after every itch inductions
|
|
Assessment of pain
Time Frame: 1 minute after every itch inductions
|
Immediately following the itch provocations, participants will be instructed to rate the pain intensity for 10 minutes using a digital visual analogue scale (VAS; eVAS Software: Aalborg, University, Denmark), on a tablet.
The scale will be measured from 0 to 100, where 0 represents 'no pain' and 100 'worst pain imaginable'.
|
1 minute after every itch inductions
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Alloknesis
Time Frame: 12 minutes after every itch inductions
|
Alloknesis sensation is measured using a standardized sensory brush (SENSELab Brush-05, Somedic AB, Hörby, Sweden) exerting a force of 200 to 400 mN.
|
12 minutes after every itch inductions
|
|
Mechanically evoked itch
Time Frame: 15 minutes after every itch inductions
|
Mechanically evoked itch is measured using three von Frey filaments of 4.08, 4.16 and 4.31 (1.0, 1.4, 2.0 g, respectively) (North Coast Medical, Gilroy, CA).
The center of the skin area is stimulated by 3 pricks, repeated 3 times in short succession.
After a total of 9 stimulations, the participants will report the itch elicited on a numerical rating scale (NRS) from 0 to 10 (0 = "no itch"; 10 = "worst imaginable itch").
|
15 minutes after every itch inductions
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- N-20210046 3rd project
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Histamine
-
University GhentResearch Foundation FlandersCompletedExercise | HistamineBelgium
-
AB BiotekHospital Clinic of BarcelonaCompleted
-
Children's Mercy Hospital Kansas CityWithdrawn
-
University of British ColumbiaRecruiting
-
University GhentResearch Foundation FlandersRecruiting
-
IPSC AGMedical University of Graz; Sciotec Diagnostic Technologies GmbHCompletedHistamine IntoleranceAustria
-
BayerCompletedHistamine H1 Antagonists, Non-SedatingGermany
-
Complexo Hospitalario Universitario de A CoruñaCompletedLower Urinary Tract Symptoms | Histamine IntoleranceSpain
-
North Texas Institute for Clinical TrialsCompletedHistamine Responsive Allergy PatientsUnited States
-
Aalborg UniversityRecruitingHistamine | CowhageDenmark
Clinical Trials on Cowhage
-
Aalborg UniversityRecruitingPain, Burning | CapsaicinDenmark
-
Aalborg UniversityRecruiting
-
Aalborg UniversityRecruitingHistamine | CowhageDenmark
-
Aalborg UniversityRecruitingHistamine | CowhageDenmark
-
Aalborg UniversityCompleted
-
Aalborg UniversityRecruitingSleep Fragmentation | Histamine | CowhageDenmark
-
Aalborg UniversityRecruitingSleep Deprivation | Histamine | CowhageDenmark
-
Aalborg UniversityNot yet recruiting
-
Aalborg UniversityRecruiting
-
Aalborg UniversityActive, not recruiting